Cytokinetics Fleshes Out Its Skeletal Business With New Partner Astellas
This article was originally published in The Pink Sheet Daily
Executive Summary
Cytokinetics and Astellas Pharma will develop and commercialize new drugs for muscle weakness under a two-year research collaboration. Cytokinetics out-licensed rights to the Phase I drug CK-2127107, but holds onto rights to its later-stage skeletal muscle activator tirasemtiv.